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Summary
Background: The cytotoxic action of leukocytes is known to be a probable cause
of the cardiac myocyte damage seen in idiopathic dilated cardiomyopathy (IDC).
Monocyte chemoattractant protein 1 (MCP-1) contributes to enhanced leukocyte
recruitment and activation resulting in chronic damage of cardiomyocytes. MCP-1
has been reported to be dynamically regulated in IDC and may contribute to the
deterioration of left ventricular function. In addition, a polymorphism at −2518
(G/A) in the MCP-1 gene affects the level of MCP-1 expression in response to an
inﬂammatory stimulus.
Methods and results: We genotyped the polymorphism at −2518 G/A in the MCP-1
gene in 73 Japanese patients with nonfamilial IDC and 349 healthy controls. The
distribution of the MCP-1 genotypes in the IDC patients differed signiﬁcantly from
the controls (p = 0.016). In a dominant G allele model, there was a signiﬁcant differ-
ence in the distribution of genotypes between the two groups (p < 0.01). The odds
ratio for nonfamilial IDC associated with the GG vs. non-GG genotype was 10.4 (95%
CI = 1.7—64.5) after adjustment for the confounding factors.
∗ Corresponding author. Tel.: +81 89 960 5302; fax: +81 89 960 5306.
E-mail address: aogimoto@m.ehime-u.ac.jp (A. Ogimoto).
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ntroduction
diopathic dilated cardiomyopathy (IDC) is a pri-
ary heart muscle disease characterized by left
entricular dilatation and systolic dysfunction, with
econdary diastolic dysfunction. Although inher-
ted gene defects account for 25—30% of IDC cases
1], most cases of IDC are sporadic and consis-
ent with multifactorial genetic traits (nonfamilial
DC) [2,3]. As for the pathogenesis of nonfamilial
DC, persistent viral infection [3] and immunologi-
al abnormalities including autoimmunity [4] have
een postulated. Because genetic factors inﬂuence
he immune response to autoantigens as well as
o foreign antigens, polymorphism in the genes
nvolved in inﬂammation has been investigated
n IDC, especially focusing on HLA [5]. Recent
xperimental and clinical data suggest a causal
elationship between myocarditis and IDC, indi-
ating that a chronic inﬂammatory process may
e responsible for the development of IDC [3,6].
he cytotoxic action of leukocytes appears to be
he most probable cause of cardiomyocyte damage
een in chronic myocarditis and IDC [6]. Mono-
yte chemoattractant protein 1 (MCP-1) contributes
o enhanced leukocyte recruitment and activation
esulting in chronic damage of cardiomyocytes [6].
ecently, MCP-1 has been reported to be dynam-
cally regulated in IDC and may contribute to the
eterioration in left ventricular function [6]. In
ddition, a polymorphism at −2518 (G or A) in the
CP-1 gene has been reported to affect the level
f MCP-1 expression in response to an inﬂammatory
timulus [7]. However, there have been no studies
valuating the association between this polymor-
hism and nonfamilial IDC.
In the present study, we investigated MCP-1 poly-
orphism to determine whether this polymorphism
as associated with susceptibility to nonfamilial
DC.
ethodstudy subjects
he study protocols were approved by the Eth-
cal Committee of Ehime University School of
edicine, and written and informed consent was
t
p
p
r67
uggest that the G allele at −2518 in the MCP-1 gene may
susceptibility to nonfamilial IDC.
Cardiology. Published by Elsevier Ireland Ltd. All rights
btained from each subject. In this study, 73
enetically unrelated Japanese patients with non-
amilial IDC were enrolled (58 males and 15
emales, from 12 to 74 years, mean age at ini-
ial clinical evaluation 48.6± 14.4 years, mean
ody mass index 23.4± 4.2). The control group
onsisted of 349 healthy individuals free from
ny history or symptoms of cardiovascular dis-
ase (114 males and 235 females; from 52 to
7 years; mean age, 71.4± 9.4 years; mean body
ass index, 23.1± 3.2). All healthy individuals
ere recruited from the Shimanami Health Pro-
oting Program (J-SHIPP) [8]. All patients with
DC were diagnosed at Ehime University Hospital
y examinations with 12-lead electrocardiogra-
hy, transthoracic echocardiography, and cardiac
atheterization. These patients also met the def-
nition and classiﬁcation proposed by the 1995
orld Health Organization/International Society
nd the Federation of Cardiology Task Force [9].
he exclusion criteria were as follows: (a) his-
ory of myocardial infarction; (b) history of alcohol
buse; (c) evidence of coronary heart disease or
evere valvular heart disease by cardiac catheter-
zation; and (d) active myocarditis. In addition,
atients having an apparent family history (at least
ne IDC patient in the ﬁrst-degree family relatives)
ere excluded from the study, because the IDC
henotype in these patients was attributable to
monogenic defect in the known disease-causing
enes. Any previous cardiac evaluations in the
atients enrolled with IDC were reviewed. The ini-
ial clinical status of the patients was determined
n the basis of medical records.
NA extraction and genotyping
enomic DNA was extracted from peripheral blood
amples with an extraction kit (Qiagen, Hilden,
ermany). For detection of the −2518 G/A poly-
orphism of the MCP-1 gene, genomic DNA was
mpliﬁed with primers (the forward primer 5′-CCG
GA TGT TCC CAG CAC AG-3′ and the reverse
rimer 5′-CTG CTT TGC TTG TGC CTC TT-3′) for
he distal regulatory region of the MCP-1 gene as
reviously described [7]. The −2518 G/A polymor-
hism affected PvuII digestion of the MCP-1 distal
egulatory region. The G allele gave two fragments
68
Table 1 Characteristics of patients with IDC at initial
clinical evaluation.
Age at initial clinical evaluation
(years)
48.6 (12—74)
Male/female, n 58/15
Body mass index (kg/m2) 23.4 (15—45)
NYHA functional class 2.4 (1—4)
Heart rate (beats/min) 81 (50—128)
Systolic blood pressure (mmHg) 115 (80—150)
LVDd (mm) 63 (50—102)
LVDs (mm) 51 (34—93)
Fractional shortening (%) 19 (5—32)
Mean value (minimum value−maximum value). IDC, idio-
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ppathic dilated cardiomyopathy. NYHA, New York Heart
Association. LVDd, left ventricular dimension at end-diastole.
LVDs, left ventricular dimension at end-systole.
(708 bp and 222 bp), while the A allele gave a sin-
gle 930-bp fragment [7]. Each PCR product was
electrophoresed in 3% agarose gel and DNA was visu-
alized directly with ethidium bromide staining.
Statistical methods
All statistical analyses were performed on a per-
sonal computer with SPSS Version 10.0J for Windows
(SPSS, Inc, Chicago, IL, USA). Differences in the
prevalence among groups and Hardy—Weinberg’s
equilibrium were analyzed by the chi-square
method. To analyze differences between G allele
carriers and non-carriers, the AG and GG genotypes
were pooled into one group. Association between
polymorphism and case/control status was tested
by logistic regression analysis controlling for age,
gender, and body mass index. Odds ratios were esti-
mated with 95% conﬁdence intervals as measures
of risk. A p-value of less than 0.05 was considered
statistically signiﬁcant.
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Table 2 Distribution of genotypes and alleles for polymorp
MCP-1 gene (−2518 G/A) IDC (n = 73)
Genotype, number of subjects (%)
A/A 2(3)
A/G 33 (45)
G/G 38 (52)
G dominant model, number of subjects (%)
A/A 2(3)
A/G+G/G 71 (97)
Allele, number of alleles (%)
A allele 37 (25)
G allele 109 (75)
MCP-1, monocyte chemoattractant protein-1; IDC, idiopathic dilate
a Case (IDC) compared with control (healthy Japanese).A. Ogimoto et al.
esults
he initial clinical characteristics of the patients
re summarized in Table 1. As shown in Table 2,
he genotype distributions in the patients with non-
amilial IDC and the healthy control population
ere in Hardy—Weinberg’s equilibrium. The distri-
ution of the MCP-1 genotypes was signiﬁcantly
ifferent between the patients and the healthy
ubjects (p = 0.016). There was a signiﬁcant differ-
nce in the frequency of alleles between the two
roups (p = 0.012). In a dominant G allele model,
here was a signiﬁcant difference between the two
roups (p < 0.01). Table 3 shows the odds ratios for
onfamilial IDC determined by logistic regression
nalysis. With subjects homozygotic for the A allele
onsidered as the reference category, subjects het-
rozygotic for this polymorphism had increased risk
or nonfamilial IDC. In addition, subjects homozy-
otic for the G allele had a risk of nonfamilial IDC
hat was 11 times greater than subjects homozy-
otic for the A allele. The risk was independent
f other variables, because it was even higher
hen the estimate was adjusted for all of the
ther variables (age, gender, and body mass index).
atients with two G alleles had greater risk for
onfamilial IDC than patients with no or one G
llele, which showed dose—response effect of this
olymorphism. However, we could not ﬁnd a rela-
ionship between severity of the disease and this
olymorphism.iscussion
his study is the ﬁrst report of an important asso-
iation between the MCP-1 gene polymorphism and
onfamilial IDC.
hism (−2518 G/A) in the MCP-1 gene.
Healthy Japanese
(n = 349)
p-Valuea
52(15) 0.016
149(43)
148 (42)
52(15) 0.005
297 (85)
253 (36) 0.012
445 (64)
d cardiomyopathy.
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Table 3 Odds ratios for nonfamilial IDC.
Univariate model Multivariable model
Odds ratio p-Value Odds ratio p-Value
A/A 1 1
A/G 5.8 (1.3—24.8) 0.019 9.6 (1.5—62.3) 0.017
G/G 6.7 (1.6—28.7) 0.011 11.3 (1.7—73.4) 0.011
A/A 1 1
.013
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RA/G+G/G 6.2 (1.5—26.1) 0
Multivariable odds ratios were calculated using age, gender an
The −2518 A to G polymorphism is known to
ffect the transcriptional activity of this region and
orrelates with individual differences in monocyte
CP-1 production [7]. Monocytes from individu-
ls carrying the G allele produced more MCP-1
fter treatment with IL-1 than monocytes from A/A
omozygous individuals [7]. Individuals with the G
llele may be more responsive to several inﬂam-
atory stimuli than individuals without it. The high
revalence of the G allele in our IDC patients is com-
atible with a chronic inﬂammatory process in the
athogenesis of nonfamilial IDC.
It has been reported that circulating lev-
ls of MCP-1 were increased in patients with
cute myocarditis [10], acute myocardial infarc-
ion [11], and congestive heart failure [12], and
ere also correlated with the severity of the dis-
ase. Activation and migration of leukocytes to
reas of inﬂammation are important factors in
hese immunologic responses. Seino et al. showed
he presence of MCP-1 messenger RNA in endomy-
cardial biopsy tissue obtained from patients with
DC and suggested a role for this chemokine in
he regulation of inﬂammatory cell inﬁltration into
he myocardium [13]. In addition, Lehmann et
l. reported that IDC patients with severe left
entricular dysfunction showed a 2.35-fold higher
CP-1 messenger RNA expression in endomyocar-
ial biopsy tissue when compared to IDC patients
ith milder dysfunction [6]. Furthermore, there
as a consistent trend toward a higher inﬁltra-
ion of inﬂammatory cells in IDC patients with
lower ejection fraction [6]. According to these
eports, MCP-1 may play an important role in the
athogenesis and the severity of IDC. The −2518
olymorphism was associated with the plasma level
f MCP-1 in our control subjects (J-SHIPP) [8]. How-
ver, we could not examine the circulating MCP-1
evels in the patients with IDC, which was one of
ur study limitations. Although elevated circulating
evels of MCP-1 are not speciﬁc for IDC, we believe
hat our ﬁndings support the notion that immuno-
ogic and inﬂammatory processes may be important
eatures of IDC.10.4 (1.7—64.5) 0.012
dy mass index as covariates in the logistic regression model.
We found frequencies of the G and A alleles
f 64% and 36%, respectively in healthy Japanese
ubjects. A recent study in Japanese subjects also
emonstrated that the ratio of G to A allele was 65%
o 35% [14], indicating that the G allele is indeed
he predominant type in the Asian population. How-
ver, these data are discrepant with previously
eported results for Caucasians and African Amer-
cans, where the G allele frequency was 29% and
2%, respectively [7]. Many studies, although con-
roversial, have suggested that the G/G genotype
f the MCP-1 gene is associated with the patho-
enesis of Kawasaki disease [14], asthma severity
15], coronary artery disease [16], nephritis in sys-
emic lupus erythematosus [17], and carpal-tunnel
yndrome in hemodialysis patients [18].
The number of patients in our study was small,
nd our results should be compared with those
f larger studies in various countries. Further
olecular and biological studies are needed to
larify the relation between the MCP-1 polymor-
hism and IDC. In addition, it may be important to
etermine whether there are racial differences in
nﬂammatory responses and racial variations in the
requency of this polymorphism.
In conclusion, this study strongly suggests that
he G allele at −2518 in the MCP-1 gene may be a
ovel genetic marker of susceptibility to IDC in the
apanese population.
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